• Aucun résultat trouvé

[PDF] Top 20 Voglibose for prevention of type 2 diabetes mellitus.

Has 10000 "Voglibose for prevention of type 2 diabetes mellitus." found on our website. Below are the top 20 most common "Voglibose for prevention of type 2 diabetes mellitus.".

Voglibose for prevention of type 2 diabetes mellitus.

Voglibose for prevention of type 2 diabetes mellitus.

... Figure: Prevention of type 2 diabetes in high-risk individuals with impaired glucose tolerance Drug effects, possible mechanisms, and clinical ...risk of new-onset ... Voir le document complet

3

Drug-Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus.

Drug-Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus.

... inhibitors. Diabetes Obes Metab 2012 Jan; 14 ...Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or ... Voir le document complet

21

Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus

Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus

... behalf of the REACH and REGAIN investigators a Institute of Clinical Trials and Methodology, University College London, London, UK; b Department of Endocrinology & Nutrition, Hospital de la Santa ... Voir le document complet

14

Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials.

Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials.

... Outcomes Prevention Evaluation" (HOPE) study, a total of 9297 high-risk patients (55 years of age or older) who had evidence of vascular disease or diabetes plus one other ... Voir le document complet

13

Coronary Artery Disease and Diabetes Mellitus

Coronary Artery Disease and Diabetes Mellitus

... primary prevention, patients with DM ages 40 to 75 years with an LDL–C 70 to189 mg/dL and without clinical cardiovascular disease, are one of the major statin benefit ...primary prevention, the ... Voir le document complet

30

‘Treatment-resistant’ type 2 diabetes: Which definition for clinical practice?

‘Treatment-resistant’ type 2 diabetes: Which definition for clinical practice?

... definition of standard care in T2D, restricted to the control of hyperglycaemia, is also challenging, especially given the commercialization of an increasing number of pharmacological classes, ... Voir le document complet

3

Canagliflozin: A Review in Type 2 Diabetes.

Canagliflozin: A Review in Type 2 Diabetes.

... Introduction Type 2 diabetes (T2D) is a chronic progressive metabolic disease characterized by hyperglycaemia, due to insulin resistance/insufficient insulin production [ 1 ...risk of ... Voir le document complet

20

Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.

Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.

... dence of DKA and amputation, which are both rare events. The greater number of patient-years included in these pools increased the odds of observing these ...pool of 21 placebo-/active ... Voir le document complet

9

Job strain as a risk factor for type 2 diabetes: a pooled analysis of 124,808 men and women.: Job Strain and Incident Type 2 Diabetes

Job strain as a risk factor for type 2 diabetes: a pooled analysis of 124,808 men and women.: Job Strain and Incident Type 2 Diabetes

... number of strengths including size (high statistical power even after risk factor stratification), prospective design (reducing the risk of reverse causation bias), and inclusion of well ... Voir le document complet

27

Targeting the AMPK pathway for the treatment of Type 2 diabetes.

Targeting the AMPK pathway for the treatment of Type 2 diabetes.

... Benoît Viollet, Louise Lantier, Jocelyne Devin-Leclerc, Sophie Hébrard, Chloé Amouyal, et al... Tar- geting the AMPK pathway for the treatment of Type 2 diabetes...[r] ... Voir le document complet

3

Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.

Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.

... phase of development ...safety of these once weekly GLP-1 RAs but each of three compounds already commercialized has been compared in head-to-head trials with the once- daily GLP-1 RA liraglutide (at ... Voir le document complet

32

Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus.

Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus.

... of HI with all five available DPP-4 inhibitors and GLP-1 receptor agonists (only liraglutide so ...use of glucose- lowering agents such as incretin-based therapies, via a better glucose control especially ... Voir le document complet

32

Assessment of type II diabetes mellitus using irregularly sampled measurements with missing data

Assessment of type II diabetes mellitus using irregularly sampled measurements with missing data

... parameters of the nonlinear state-space models from partially missing data using mathematical approaches such as Bayesian filters, Particle filters (PFs), Expectation-Maximization (EM) algorithms, Sequential ... Voir le document complet

19

Prevention du diabete de type 2: style de vie ou medicaments?

Prevention du diabete de type 2: style de vie ou medicaments?

... de type 2, au vu de l’“épidémie galopante” de la maladie et de sa relation étroite avec celle de ...nish Diabetes Prevention Study”) et aux Etats-Unis (“Diabetes Prevention ... Voir le document complet

5

Addition of incretin therapy to metformin in type 2 diabetes.

Addition of incretin therapy to metformin in type 2 diabetes.

... characteristics of every patient. AJS and CHU Sart-Tilman have received fees for AJS's consulting on international advisory boards from Sanofi- Aventis and AstraZeneca/Bristol-Myers Squibb, and on national ... Voir le document complet

3

Cannabinoid-1 receptor antagonists in type-2 diabetes.

Cannabinoid-1 receptor antagonists in type-2 diabetes.

... role of rimonabant in overweight/obese patients with type- 2 diabetes and a high risk of cardiovascular disease deserves ...results of RIO Diabetes and SERENADE ... Voir le document complet

13

The endocannabinoid system: a promising target for the management of type 2 diabetes.

The endocannabinoid system: a promising target for the management of type 2 diabetes.

... modulation of many central and peripheral functions ...understanding of the molecular basis of CB activity [4-6] has encouraged many pharmaceutical companies to develop synthetic CB analogues and ... Voir le document complet

49

Pharmacological management of type 2 diabetes: what's new in 2017?

Pharmacological management of type 2 diabetes: what's new in 2017?

... proposed for the management of hyperglycemia in ...benefit of hindsight, the results of the PROactive trial [primary composite endpoint (hazard ratio or HR, ...composite of all-cause ... Voir le document complet

36

DPP-4 inhibitors in the treatment of type 2 diabetes.

DPP-4 inhibitors in the treatment of type 2 diabetes.

... molecules of this class. DPP-4 is also present on the cell membrane of T lymphocytes known as ...production of interleukin (IL)-4 while IL-10 was increased ...activity of DPP-4 has not been ... Voir le document complet

27

Revealing links between gut microbiome and its fungal community in Type 2 Diabetes Mellitus among Emirati subjects: A pilot study

Revealing links between gut microbiome and its fungal community in Type 2 Diabetes Mellitus among Emirati subjects: A pilot study

... impact of different clinical var- iables (age, BMI, weight, diet and gender) and disease state over alpha diversity ...significance of diversity changes after excluding the variability explained by age ... Voir le document complet

12

Show all 10000 documents...